Crinetics Pharmaceuticals (CRNX) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRNX shares.
View CRNX analyst ratings or view top-rated stocks.

5 brokers have issued 1 year target prices for Crinetics Pharmaceuticals' shares. Their CRNX share price forecasts range from $35.00 to $56.00. On average, they predict the company's stock price to reach $45.50 in the next year. This suggests a possible upside of 106.7% from the stock's current price.
View analysts price targets for CRNX or view top-rated stocks among Wall Street analysts.

Crinetics Pharmaceuticals' stock was trading at $18.30 at the start of the year. Since then, CRNX stock has increased by 20.3% and is now trading at $22.01.
View the best growth stocks for 2023 here.

Crinetics Pharmaceuticals saw a drop in short interest in May. As of May 15th, there was short interest totaling 3,440,000 shares, a drop of 18.9% from the April 30th total of 4,240,000 shares. Based on an average daily volume of 449,500 shares, the days-to-cover ratio is presently 7.7 days.
View Crinetics Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our CRNX earnings forecast.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) issued its earnings results on Friday, November, 5th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by $0.01. Crinetics Pharmaceuticals had a negative trailing twelve-month return on equity of 52.55% and a negative net margin of 4,090.69%.

ETFs with the largest weight of Crinetics Pharmaceuticals (NASDAQ:CRNX) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and Invesco Nasdaq Biotechnology ETF (IBBQ).

6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

(CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Crinetics Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.33%), Wellington Management Group LLP (6.73%), Perceptive Advisors LLC (6.58%), State Street Corp (4.11%), Braidwell LP (3.74%) and First Light Asset Management LLC (3.00%). Insiders that own company stock include Ajay Madan, Dana Pizzuti, Jeff E Knight, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers and Stephen F Betz.
View institutional ownership trends.

Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRNX stock can currently be purchased for approximately $22.01.

Crinetics Pharmaceuticals (NASDAQ:CRNX) has a market capitalization of $1.19 billion and generates $4.74 million in revenue each year. The company earns $-163,920,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis.

The company employs 143 workers across the globe.

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The official website for the company is www.crinetics.com. The company can be reached via phone at (858) 450-6464 or via email at ir@crinetics.com.